Search Results for: 2017 GLOBAL DRUG DELIVERY FORMULATION
Articles
EXECUTIVE INTERVIEW - Avista Pharma Solutions: Experience, Responsiveness & Expanded Capacity Driving Growth January 13, 2017
Patrick Walsh, CEO of Avista Pharma Solutions, talks about his company’s range of capabilities and what is driving growth in this dynamic industry.
Flamel Technologies Completes Cross-Border Merger & Becomes Avadel Pharmaceuticals January 6, 2017
Flamel Technologies SA, completed its previously announced cross-border merger with and into its wholly owned Irish subsidiary, Avadel Pharmaceuticals plc,...SteadyMed Announces Completion of Pre-NDA Submission Manufacturing Activities September 2, 2016
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value...INDUSTRY PERSPECTIVES - What Surprised You the Most This Past Year?: Your Colleague’s Perspectives June 30, 2016
The Global Formulation Report in this issue provided some interesting data on what has been happening in a number of key sectors over the past year. We thought it would be intriguing to hear what some of your colleagues said surprised them most.
Aegerion Pharmaceuticals & QLT Agree to Strategic Merger June 20, 2016
Aegerion Pharmaceuticals, Inc. and QLT Inc. recently announced they have entered into a definitive merger agreement under which Aegerion will...Ajinomoto Althea Expands Manufacturing Capabilities to ADC Fill Finish & Bioconjugation October 16, 2015
Ajinomoto Althea, Inc. recently announced it is expanding its existing biological drug product manufacturing operations to include highly active materials...The CDMO Market: Implications of Patheon's IPO June 10, 2015
By: Patricia Van Arnum, DCAT Editorial Director, posted Tue, Jun 09, 2015 04:42 AM Patheon's announcement this week that it plans to...PARTICLE AGGREGATION ANALYSIS - Biologics & Particulates: Identification & Control in the Product Lifecycle March 30, 2015
Zabin Younes says that traditional tools, such as SEC and DSC, have been used in formulation screening; however, to ensure a control of particulate counts, it is important to use the full range of tools to ensure all types and sizes of particles and aggregates are assessed and accounted.
Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market April 8, 2014
The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market...SPECIAL FEATURE- Analytical Testing of Biologics & Biosimilars March 5, 2014
Contributor Cindy H. Dubin talks with some of the leading experts in the industry about the importance of outsourcing analytical testing in the biologic/biosimilar space, the associated challenges, and how to ensure products get to market safely and quickly.
Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market January 15, 2014
The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market...SPECIAL REPORT - Prefilled Syringes & Parenteral Contract Manufacturing: Improving for Flexibility & Customization April 30, 2013
Special Feature: Contributor Cindy H. Dubin speaks with prefilled syringe manufacturers as well as contract parenteral manufacturers who share their thoughts about the delivery challenges associated with high-viscous, high-volume formulations.
2/13/2013 February 11, 2013
Frost & Sullivan Sees Urgent Need for Cancer Diagnostics Tests; Finds Unmet Need for Key Disorders The range of potential...12/12/2012 December 10, 2012
TNF Inhibitors Lay Groundwork for Next-Generation of Disease-Modifying Anti-Rheumatic Drugs The challenges inherent in the pharmacological management of rheumatic diseases...11/28/2012 November 26, 2012
CoreRx & ViroPro Announce Agreement CoreRx, Inc. and Viropro, Inc. recently announced the two companies have entered into a Reciprocal...11/14/2012 November 8, 2012
A Note to The Pharmaceutical Industry Upon The Re-Election of Barack Obama By: Matthew Herper, Forbes Staff, mherper@forbes.com I've covered...10/30/2012 October 25, 2012
Arthritis Signifies a Vast Untouched Market, Finds Frost & Sullivan Tumor necrosis factor (TNF) inhibitors are currently the only therapeutic...7/12/2011 July 6, 2011
Evotec & Roche to Jointly Develop Biomarkers in Oncology Evotec AG and Roche recently announced a collaboration in novel...2/15/2011 February 10, 2011
BASF & Medi-Solve Coatings to Develop Multifunctional Coating Solutions for Medical Devices BASF Future Business GmbH and Medi-Solve Coatings LLC...Outsourcing Drug Development & Production: Technology-Driven Drug Delivery Systems for Small Molecules at Losan Pharma
Due to the increasing demand for drug delivery systems that are able to improve the properties of low soluble, poor permeable, or highly dosed new and existing drug substances, technology-driven CDMOs can offer a wide range of technology platforms to overcome such challenges….
